FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to hepatology, and can be used for screening of patients suspected of liver disease. To this end, 13C-metacetin respiratory test. If the cumulative dose value 13C the specified test at 30th minute <5.65 % hepatic cirrhosis is determined.
EFFECT: method enables non-invasive determination of hepatic cirrhosis, which enables eliminating the risk of developing complications.
1 cl, 1 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR DETERMINING DEGREE OF LIVER FIBROSIS | 2018 |
|
RU2675341C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF STEATOSIS AND NON-ALCOHOLIC STEATOHEPATITIS IN FEMALES | 2020 |
|
RU2744021C1 |
| METHOD FOR DETERMINING A STAGE OF HEPATIC FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS C | 2019 |
|
RU2722877C1 |
| METHOD FOR MONITORING HEPATIC FIBROSIS CASES IN CHRONIC HEPATITIS C PATIENTS | 2005 |
|
RU2309406C2 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF LIVER STEATOSIS AND NON-ALCOHOLIC STEATOHEPATITIS IN MEN | 2020 |
|
RU2753455C1 |
| METHOD OF DIFFERENTIAL DIAGNOSTICS OF DIFFUSE DISEASES OF LIVER | 2011 |
|
RU2482792C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF CHRONIC HEPATITIS C AND AUTOIMMUNE LIVER DISEASES IN PATIENTS WITH SEVERE FIBROSIS AND CIRRHOSIS | 2024 |
|
RU2834898C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF CHRONIC HEPATITIS B AND CHRONIC HEPATITIS C IN PATIENTS WITH SEVERE FIBROSIS AND CIRRHOSIS | 2024 |
|
RU2835987C1 |
| METHOD FOR PREDICTION OF LIVER CIRRHOSIS IN PATIENTS WITH CHRONIC HEPATITIS C | 2024 |
|
RU2834154C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF CHRONIC HEPATITIS B, CHRONIC HEPATITIS C AND AUTOIMMUNE LIVER DISEASES IN PATIENTS WITH SEVERE FIBROSIS AND CIRRHOSIS | 2024 |
|
RU2834902C1 |
